1. Martinez E, Taminiau B., Rodriguez C., Daube G. Gut Microbiota Composition Associated with Clostridioides difficile Colonization and Infection. Pathogens. 2022;11(7):781. doi: 10.3390/pathogens11070781
2. Tagliaferri AR, Murray K, Michael P. A Case of Pseudomembranous Colitis of Unknown Etiology. Cureus. 2022 ; 14(2): e21914. doi: 10.7759/cureus.21914
3. Chandrasekaran R., Lacy DB. The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev. 2017;41(6):723-750. doi: 10.1093/femsre/fux048
4. Abdul Jabbar S, Sundaramurthi S, Elamurugan TP, Goneppanavar M, Nelamangala RVP. An Unusual Presentation of Pseudomembranous Colitis. Cureus. 2019;11(4):e4570. doi: 10.7759/cureus.4570
5. Czepiel J, Drozdz M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38(7):1211-1221. doi: 10.1007/s10096-019-03539-6
6. De Roo A.C, Regenbogen SE. Clostridium difficile Infection: An Epidemiology Update. Clin Colon Rectal Surg. 2020;33(2):49-57. doi: 10.1055/s-0040-1701229
7. Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Preevot 1938. Anaerobe. 2016;40:95-9. doi: 10.1016/j.anaerobe.2016.06.008
8. Khurana S, Kahl A, Yu K, DuPont AW. Recent advances in the treatment of Clostridioides difficile infection: the ever-changing guidelines. Fac Rev. 2020; 9: 13. doi: 10.12703/b/9-13
9. Couturier J, Franconeri L, Janoir C, Ferraris L, Syed-Zaidi R, Youssouf A et al. Characterization of Non-Toxigenic Clostridioides difficile Strains Isolated from Preterm Neonates and In Vivo Study of Their Protective Effect. J Clin Med. 2020;9(11):3650. doi: 10.3390/jcm9113650
10. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; 66(7): e1–e48. doi: 10.1093/cid/cix1085
11. Baktash A, Terveer EM, Zwittink RD, Hornung BVH, Corver J, Kuijper EJ, Smits WK. Mechanistic insights in the success of fecal microbiota transplants for the treatment of Clostridium difficile infections. Front Microbiol. 2018;9:1242. doi: 10.3389/fmicb.2018.01242
12. Kochan TJ, Somers MJ, Kaiser AM, Shoshiev MS, Hagan AK, Hastie JL et al. Intestinal calcium and bile salts facilitate germination of Clostridium difficile spores. PLoS Pathog. 2017; 13(7): e1006443. doi: 10.1371/journal.ppat.1006443
13. Sehgal K, Khanna S. Gut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface. Therap Adv Gastroenterol. 2021; 14. doi: 10.1177/1756284821994736
14. Thornton CS, Rubin JE, Greninger AL, Peirano G, Chiu CY, Pillai DR. Epidemiological and genomic characterization of community-acquired Clostridium difficile infections. BMC Infect Dis 2018; 18: 443. doi: 10.1186/s12879-018-3337-9
15. Fu Y, Luo Y, Grinspan AM. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol. 2021; 14. doi: 10.1177/17562848211016248
16. Gazzola A, Panelli S, Corbella M, Merla C, Comandatore F, De Silvestri A et al. Microbiota in Clostridioides difficile-Associated Diarrhea: Comparison in Recurrent and Non-Recurrent Infections. Biomedicines. 2020 Sep; 8(9): 335. doi: 10.3390/biomedicines8090335
17. Singh T, Bedi P, Bumrah K, Singh J, Rai M, Seelam S. Updates in treatment of recurrent Clostridium difficile infection. J Clin Med Res. 2019;11(7):465–471. doi: 10.14740/jocmr3854
18. Успенский Ю.П., Барышникова Н.В. Антибиотик- ассоциированная диарея в условиях стационара: частота встречаемости и вопросы профилактики. Медицинский алфавит. 2021;(20):35-37. doi: 10.33667/2078-5631-2021-20-35-37
19. Guh AY, Mu Y, Winston LG, Lohnston H, Olson D, Farley MM et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med 2020; 382: 1320–1330. doi: 1056/NEJMoa1910215
20. Centers for Disease Control and Prevention. 2018 Annual report for the emerging infections program for Clostridioides difficile infection. Atlanta, GA: CDC, 2020.
21. Baker SJ, Chu DI. Physical, Laboratory, Radiographic, and Endoscopic Workup for Clostridium difficile Colitis. Clin Colon Rectal Surg. 2020; 33(2): 82–86. doi: 10.1055/s-0039-3400474.
22. Czepiel J, Biesiada G, Dróżdż M, Gdula- Argasinska J, Zuranska J, Marchewka J et al. The presence of IL-8 +781 T/C polymorphism is associated with the parameters of severe Clostridium difficile infection. Microb Pathog. 2018;114:281–285. doi: 10.1016/j.micpath.2017.11.066
23. Kwon JH, Reske KA, Hink T, Burnham CAD, Dubberke ER. Evaluation of Correlation between Pretest Probability for Clostridium difficile Infection and Clostridium difficile Enzyme Immunoassay Results. J Clin Microbiol. 2017; 55(2): 596–605. doi: 10.1128/JCM.02126-16
24. Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clinical Infectious Diseases. 2021;73(5):e1029-e1044. doi: 10.1093/cid/ciab549